載入...
Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely impact overall survival. T...
Na minha lista:
| 發表在: | J Invest Dermatol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4567913/ https://ncbi.nlm.nih.gov/pubmed/26016894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.198 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|